Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Hematologic Malignancies

NCT05279859 is registered in ClinicalTrials.gov with Erasca, Inc. as lead sponsor.

NCT NCT05279859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05279859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Hematologic Malignancies
Lead sponsor
Erasca, Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
March 15, 2022
Completion date
June 1, 2025
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia